News
Sanofi announces positive data for frexalimab in relapsing MS
Sanofi has reported positive new data from a mid-stage study of its investigational anti-CD40L antibody in patients with relapsing forms of multiple sclerosis (MS).
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Sanofi has reported positive new data from a mid-stage study of its investigational anti-CD40L antibody in patients with relapsing forms of multiple sclerosis (MS).